Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
Holding IONS?
Track your performance easily
IONS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.33 - $54.44
Previous Close$35.91
Volume1.00M
Average Volume (3M)1.44M
Market Cap
$5.67B
Enterprise Value$3.40B
Total Cash (Recent Filing)$2.48B
Total Debt (Recent Filing)$212.84M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Feb 19, 2025EPS Estimate
-$1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.44
Shares Outstanding157,897,287
10 Day Avg. Volume1,711,268
30 Day Avg. Volume1,436,851
Standard Deviation0.09
R-Squared0.04
Alpha-0.00984
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)8.55
Price to Sales (P/S)7.06
Price to Cash Flow (P/CF)-12.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.23
Enterprise Value/Gross Profit4.37
Enterprise Value/Ebitda-12.55
Forecast
1Y Price Target
$61.75Price Target Upside71.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Ionis Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
FDA ApprovalIonis announced FDA approval of olezarsen (Tryngolza) for the treatment of familial chylomicronemia syndrome (FCS), marking it as the first FDA approved therapy for this rare disease in the US.
Financial PositionThe company has a net debt to total capital ratio of 0%, indicating a strong financial position.
Market PotentialThe FCS approval provides Ionis with a hedge against future data, suggesting potential for significant US sales if ultra-orphan pricing is maintained.
Bears Say
Launch DelaysThe launch of eplontersen ATTR-CM has been delayed to 2027, which impacts potential revenue timelines.
Price Target AdjustmentThe updated guidance for the Phase 3 CARDIO-TTRansform trial has led to a reduction in the price target from $57 to $55.
Revenue ExpectationsTRYNGOLZA revenues are modeled at $27M, just below the current expectations.
---
Ownership Overview
0.74% Insiders
38.63% Mutual Funds
38.42% Other Institutional Investors
7.22% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $33.33 and its highest was $54.44 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Currently, no data Available
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Feb 19, 2025 which is in 51 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported -$0.95 earnings per share for the quarter, beating the consensus estimate of -$1.126 by $0.176.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -$1.11.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 157,897,300 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of -$0.95 in its last earnings report, beating expectations of -$1.126. Following the earnings report the stock price went up 0.619%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Among the largest hedge funds holding Ionis Pharmaceuticals’s share is Tweedy Browne CO LLC. It holds Ionis Pharmaceuticals’s shares valued at 138M.
---
Ionis Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.75 (71.96% Upside)
$61.75 (71.96% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 531.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $181.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 26.3%
Last 30 Days ▲ 26.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.40%
12-Months-Change
Fundamentals
Return on Equity
-73.33%
Trailing 12-Months
Asset Growth
5.01%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.
---
IONS Company Deck
---
IONS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with substantial progress in pipeline development and upcoming product launches. Despite a slight decrease in quarterly revenue and increased operating expenses, the company is well-positioned for future growth with a strong cash position and strategic investments.Read More>---
IONS Revenue Breakdown
60.82% R&D
39.18% Commercial
---
IONS Stock 12 Month Forecast
Average Price Target
$61.75
▲(71.96% Upside)
Technical Analysis
Alnylam Pharma
―
Sarepta Therapeutics
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Best Analysts Covering IONS
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+15.34%
reiterated a buy rating 28 days ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +15.34% per trade.
---